| Year |
Citation |
Score |
| 2022 |
Greco TM, Secker C, Ramos ES, Federspiel JD, Liu JP, Perez AM, Al-Ramahi I, Cantle JP, Carroll JB, Botas J, Zeitlin SO, Wanker EE, Cristea IM. Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of Huntington disease. Cell Systems. PMID 35148841 DOI: 10.1016/j.cels.2022.01.005 |
0.372 |
|
| 2021 |
Malaiya S, Cortes-Gutierrez M, Herb BR, Coffey SR, Legg SRW, Cantle JP, Colantuoni C, Carroll JB, Ament SA. Single-Nucleus RNA-Seq Reveals Dysregulation of Striatal Cell Identity Due to Huntington's Disease Mutations. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 34011527 DOI: 10.1523/JNEUROSCI.2074-20.2021 |
0.334 |
|
| 2020 |
Minikel EV, Zhao HT, Le J, O'Moore J, Pitstick R, Graffam S, Carlson GA, Kavanaugh MP, Kriz J, Kim JB, Ma J, Wille H, Aiken J, McKenzie D, Doh-Ura K, ... ... Carroll JB, et al. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Research. PMID 32776089 DOI: 10.1093/Nar/Gkaa616 |
0.444 |
|
| 2019 |
Raymond GJ, Zhao HT, Race B, Raymond LD, Williams K, Swayze EE, Graffam S, Le J, Caron T, Stathopoulos J, O'Keefe R, Lubke LL, Reidenbach AG, Kraus A, Schreiber SL, ... ... Carroll JB, et al. Antisense oligonucleotides extend survival of prion-infected mice. Jci Insight. 5. PMID 31361599 DOI: 10.1172/Jci.Insight.131175 |
0.42 |
|
| 2018 |
Ament SA, Pearl JR, Cantle JP, Bragg RM, Skene PJ, Coffey SR, Bergey DE, Wheeler VC, MacDonald ME, Baliga NS, Rosinski J, Hood LE, Carroll JB, Price ND. Transcriptional regulatory networks underlying gene expression changes in Huntington's disease. Molecular Systems Biology. 14: e7435. PMID 29581148 DOI: 10.15252/Msb.20167435 |
0.404 |
|
| 2018 |
Kovalenko M, Milnerwood A, Giordano J, St Claire J, Guide JR, Stromberg M, Gillis T, Sapp E, DiFiglia M, MacDonald ME, Carroll JB, Lee JM, Tappan S, Raymond L, Wheeler VC. HttQ111/+ Huntington's Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction. Journal of Huntington's Disease. 7: 17-33. PMID 29480209 DOI: 10.3233/Jhd-170282 |
0.473 |
|
| 2018 |
Minnig S, Bragg RM, Tiwana HS, Solem WT, Hovander WS, Vik ES, Hamilton M, Legg SRW, Shuttleworth DD, Coffey SR, Cantle JP, Carroll JB. Early Detection of Apathetic Phenotypes in Huntington's Disease Knock-in Mice Using Open Source Tools. Scientific Reports. 8: 2304. PMID 29396492 DOI: 10.1038/S41598-018-20607-7 |
0.486 |
|
| 2017 |
Coffey SR, Bragg RM, Minnig S, Ament SA, Cantle JP, Glickenhaus A, Shelnut D, Carrillo JM, Shuttleworth DD, Rodier JA, Noguchi K, Bennett CF, Price ND, Kordasiewicz HB, Carroll JB. Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease. Plos One. 12: e0175968. PMID 28453524 DOI: 10.1371/Journal.Pone.0175968 |
0.565 |
|
| 2017 |
Ament SA, Pearl JR, Grindeland A, St Claire J, Earls JC, Kovalenko M, Gillis T, Mysore J, Gusella JF, Lee JM, Kwak S, Howland D, Lee MY, Baxter D, Scherler K, ... ... Carroll JB, et al. High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgrounds. Human Molecular Genetics. PMID 28334820 DOI: 10.1093/Hmg/Ddx006 |
0.512 |
|
| 2017 |
Bragg RM, Coffey SR, Weston RM, Ament SA, Cantle JP, Minnig S, Funk CC, Shuttleworth DD, Woods EL, Sullivan BR, Jones L, Glickenhaus A, Anderson JS, Anderson MD, Dunnett SB, ... ... Carroll JB, et al. Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.Htt(Q111/+) model of Huntington's disease. Scientific Reports. 7: 41570. PMID 28176805 DOI: 10.1038/Srep41570 |
0.456 |
|
| 2015 |
Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington's disease. The Lancet. Neurology. 14: 1135-42. PMID 26466780 DOI: 10.1016/S1474-4422(15)00177-5 |
0.45 |
|
| 2015 |
Carroll JB, Deik A, Fossale E, Weston RM, Guide JR, Arjomand J, Kwak S, Clish CB, MacDonald ME. HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation. Plos One. 10: e0134465. PMID 26295712 DOI: 10.1371/Journal.Pone.0134465 |
0.351 |
|
| 2014 |
Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. Plos One. 9: e107434. PMID 25207939 DOI: 10.1371/Journal.Pone.0107434 |
0.754 |
|
| 2014 |
Southwell AL, Skotte NH, Kordasiewicz HB, Østergaard ME, Watt AT, Carroll JB, Doty CN, Villanueva EB, Petoukhov E, Vaid K, Xie Y, Freier SM, Swayze EE, Seth PP, Bennett CF, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2093-106. PMID 25101598 DOI: 10.1038/Mt.2014.153 |
0.753 |
|
| 2014 |
Weston R, Rodier J, Coffey S, Glickenhaus A, Boros L, MacDonald M, Carroll J. B30 Investigating Hepatic Dysfunction In The Httq111/+ Mouse With A Perturbagen-based Primary Hepatocyte System Journal of Neurology, Neurosurgery & Psychiatry. 85: A19-A20. DOI: 10.1136/Jnnp-2014-309032.58 |
0.38 |
|
| 2013 |
Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, Villanueva EB, Kovalik V, Xie Y, Pouladi MA, Collins JA, Yang XW, Franciosi S, Hayden MR. A fully humanized transgenic mouse model of Huntington disease. Human Molecular Genetics. 22: 18-34. PMID 23001568 DOI: 10.1093/Hmg/Dds397 |
0.77 |
|
| 2011 |
Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 2178-85. PMID 21971427 DOI: 10.1038/Mt.2011.201 |
0.745 |
|
| 2011 |
Carroll JB, Southwell AL, Graham RK, Lerch JP, Ehrnhoefer DE, Cao LP, Zhang WN, Deng Y, Bissada N, Henkelman RM, Hayden MR. Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Molecular Neurodegeneration. 6: 59. PMID 21854568 DOI: 10.1186/1750-1326-6-59 |
0.757 |
|
| 2011 |
Huang K, Sanders SS, Kang R, Carroll JB, Sutton L, Wan J, Singaraja R, Young FB, Liu L, El-Husseini A, Davis NG, Hayden MR. Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14. Human Molecular Genetics. 20: 3356-65. PMID 21636527 DOI: 10.1093/Hmg/Ddr242 |
0.549 |
|
| 2011 |
Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiology of Disease. 43: 257-65. PMID 21458571 DOI: 10.1016/J.Nbd.2011.03.018 |
0.576 |
|
| 2010 |
Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O, MacDonald M, Wellington C, DiDonato S, Hayden M, Cattaneo E. Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 10844-50. PMID 20702713 DOI: 10.1523/Jneurosci.0917-10.2010 |
0.659 |
|
| 2010 |
Pouladi MA, Carroll J, dar Santos R, Bertram L, Hayden MR. B12 Treatment with arimoclomol does not lead to rescue of motor or striatal deficits in the YAC128 mouse model of Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A14.2-A14. DOI: 10.1136/Jnnp.2010.222596.12 |
0.694 |
|
| 2009 |
Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. American Journal of Human Genetics. 84: 351-66. PMID 19249009 DOI: 10.1016/J.Ajhg.2009.02.003 |
0.743 |
|
| 2009 |
Joshi PR, Wu NP, André VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2414-27. PMID 19244517 DOI: 10.1523/Jneurosci.5687-08.2009 |
0.564 |
|
| 2008 |
Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, Singaraja RR, Overall CM, Hayden MR. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Human Molecular Genetics. 17: 2390-404. PMID 18445618 DOI: 10.1093/Hmg/Ddn139 |
0.66 |
|
| 2008 |
Lerch JP, Carroll JB, Dorr A, Spring S, Evans AC, Hayden MR, Sled JG, Henkelman RM. Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. Neuroimage. 41: 243-51. PMID 18387826 DOI: 10.1016/J.Neuroimage.2008.02.019 |
0.501 |
|
| 2008 |
Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM. Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage. 39: 32-9. PMID 17942324 DOI: 10.1016/J.Neuroimage.2007.08.033 |
0.542 |
|
| 2007 |
Valenza M, Carroll JB, Leoni V, Bertram LN, Björkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human Molecular Genetics. 16: 2187-98. PMID 17613541 DOI: 10.1093/Hmg/Ddm170 |
0.588 |
|
| 2007 |
Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease. 26: 189-200. PMID 17276692 DOI: 10.1016/J.Nbd.2006.12.010 |
0.697 |
|
| Show low-probability matches. |